KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

– Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout Expected in Q4 –

Company Funded Into 2025 With NDA Planned for H1 2024 –

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal year ended April 30, 2023.

“We have made a great deal of progress over the last fiscal year in the development of sebetralstat,” said Andrew Crockett, Chief Executive Officer of KalVista. “Consistent with prior guidance, we have achieved the target enrollment for the sebetralstat phase 3 KONFIDENT trial. We expect to have data readout in the fourth quarter of this year and submit an NDA in the first half of 2024. In addition, we continue to expand the potential of our oral Factor XIIa inhibitor program beyond HAE by presenting positive preclinical data in several other therapeutic areas, including thrombosis. We remain well-capitalized, with funding into 2025.”

Fiscal 2023 and Recent Business Highlights:

Sebetralstat

  • In June 2023, the Company achieved its enrollment target of 114 patients in the phase 3 KONFIDENT trial. KalVista expects data from the event-driven trial in the fourth quarter of 2023 and, if successful, anticipates submitting an NDA to the FDA in the first half of 2024.
  • Presented real-world patient data at the 13th C1-inhibitor Deficiency & Angioedema Workshop and the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI) showing the persistent burden in patients receiving modern long-term prophylaxis, and the challenges associated with on-demand treatment decision-making during HAE attacks.
  • Received guidance from the Japanese regulatory authority (PMDA) on the clinical development pathway to a regulatory submission in that country. KONFIDENT is the first pivotal phase 3 global trial in HAE to include Japanese sites and patients.
  • Published sebetralstat phase 2 data evaluating the efficacy and safety of oral sebetralstat for the on-demand treatment of hereditary angioedema (HAE) attacks in The Lancet.
  • Reported positive phase 1 data for an oral disintegrating tablet (ODT) formulation of sebetralstat. KalVista also received FDA feedback on its proposed ODT development program to support a supplemental NDA, which did not include a requirement to conduct efficacy trials.
  • Initiated KONFIDENT-S, a two-year open-label extension trial assessing the long-term safety and tolerability profile of sebetralstat. The study will also examine the potential use of sebetralstat as a treatment for short-term prophylaxis in medical and dental procedures.

Oral Factor XIIa Inhibitor Program

  • Reported promising preclinical data for the Company’s oral factor XIIa inhibitor program at the 2023 Congress of The International Society on Thrombosis and Haemostasis (ISTH). Data showed that KalVista’s potent and selective FXIIa inhibitor with high oral availability inhibited thrombosis in mice, the first oral FXIIa inhibitor shown to protect against thrombosis.

Organizational

  • Promoted Benjamin L. Palleiko to the role of President of KalVista. In addition to his other duties, Mr. Palleiko will now be responsible for leading broadly the Company’s future business growth, including development of the commercial organization for the intended worldwide launch of sebetralstat.
  • Raised $58 million in a registered direct offering, with the intent to use those proceeds to fund clinical trials, commercial sales development, research, working capital, capital expenditures and other general corporate purposes. With the financing, KalVista now expects to be able to fund operations into 2025.
  • Appointed Brian J.G. Pereira, M.D. as Chairman of the KalVista Board of Directors.

Fourth Quarter and Full Year Financial Results:

  • Revenue: No revenue was recognized for the three months and fiscal years ended April 30, 2023, or April 30, 2022, respectively.
  • R&D Expenses: Research and development expenses were $24.0 million for the three months ended April 30, 2023, compared to $19.2 million for the same period in the prior fiscal year. Research and development expenses were $80.3 million for the fiscal year ended April 30, 2023, compared to $70.2 million for the prior fiscal year. The increase in spending in the fiscal year ended April 30, 2023 primarily reflects increased costs related to the ongoing clinical trial for sebetralstat, increased preclinical spending, and a headcount driven increase in personnel costs.
  • G&A Expenses: General and administrative expenses were $7.8 million for the three months ended April 30, 2023, compared to $7.6 million for the same period in the prior fiscal year. General and administrative expenses were $30.6 million for the fiscal year ended April 30, 2023, compared to $26.4 million for the prior fiscal year. The increase in G&A expenses was primarily due to an increase in commercial strategy expenses and to a lesser extent, increases in public relations costs and other administrative costs.
  • Net Loss: Net loss was $26.3 million, or $(0.77) per weighted average basic and diluted share, for the three months ended April 30, 2023, compared to net loss of $24.1 million, or $(0.98) per weighted average basic and diluted share for the same period in the prior fiscal year. Net loss was $92.9 million, or $(3.33) per weighted average basic and diluted share for the fiscal year ended April 30, 2023, compared to net loss of $82.3 million, or $(3.36) per weighted average basic and diluted share in the prior fiscal year. The increase in net loss and net loss per share primarily resulted from the increase in operating expenses, primarily research and development.
  • Cash position: Cash, cash equivalents and marketable securities were $149.4 million on April 30, 2023, compared to $166.2 million on April 30, 2022. The decrease in the net cash position over the fiscal year is primarily due to increased operating expenses.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

For more information about KalVista, please visit www.kalvista.com.

For more information on the sebetralstat HAE on-demand phase 3 KONFIDENT study, please visit www.konfidentstudy.com.

Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, timing or outcomes of communications with the FDA, our expectations about safety and efficacy of our product candidates and timing of clinical trials and its results, our ability to commence clinical studies or complete ongoing clinical studies, including our Phase 3 KONFIDENT trial, and to obtain regulatory approvals for sebetralstat and other candidates in development, the success of any efforts to commercialize sebetralstat, the ability of sebetralstat and other candidates in development to treat HAE or other diseases, and the future progress and potential success of our oral Factor XIIa program. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2022, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

KalVista Pharmaceuticals Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
 

April 30,

 

April 30,

 

2023

 

 

 

2022

 

Assets
Current assets:
Cash and cash equivalents

$

56,238

 

$

30,732

 

Marketable securities

 

93,137

 

 

135,470

 

Research and development tax credit receivable

 

16,568

 

 

14,098

 

Prepaid expenses and other current assets

 

6,383

 

 

13,347

 

Total current assets

 

172,326

 

 

193,647

 

Property and equipment, net

 

2,948

 

 

2,178

 

Right of use assets

 

7,822

 

 

7,862

 

Other assets

 

106

 

 

193

 

Total assets

$

183,202

 

$

203,880

 

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

$

4,817

 

$

3,638

 

Accrued expenses

 

9,128

 

 

6,961

 

Lease liability - current portion

 

1,087

 

 

977

 

Total current liabilities

 

15,032

 

 

11,576

 

Long-term liabilities:

Lease liability - net of current portion

 

7,145

 

 

7,211

 

Total long-term liabilities

 

7,145

 

 

7,211

 

Stockholders’ equity:
Common stock, $0.001 par value

 

34

 

 

25

 

Additional paid-in capital

 

507,133

 

 

439,104

 

Accumulated deficit

 

(343,082

)

 

(250,175

)

Accumulated other comprehensive loss

 

(3,060

)

 

(3,861

)

Total stockholders’ equity

 

161,025

 

 

185,093

 

Total liabilities and stockholders' equity

$

183,202

 

$

203,880

 

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(Unaudited)
 
 

Three Months Ended

 

Years Ended

April 30,

 

April 30,

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

 
Revenue

$

 

$

 

$

 

$

 

Operating expenses:
Research and development

 

23,951

 

 

19,213

 

 

80,276

 

 

70,167

 

General and administrative

 

7,777

 

 

7,598

 

 

30,595

 

 

26,446

 

Total operating expenses

 

31,728

 

 

26,811

 

 

110,871

 

 

96,613

 

Operating loss

 

(31,728

)

 

(26,811

)

 

(110,871

)

 

(96,613

)

 
Other income:
Interest income

 

808

 

 

268

 

 

2,232

 

 

1,090

 

Foreign currency exchange rate (loss) gain

 

327

 

 

(1,008

)

 

90

 

 

(1,537

)

Other income

 

4,288

 

 

3,438

 

 

15,642

 

 

14,721

 

Total other income

 

5,423

 

 

2,698

 

 

17,964

 

 

14,274

 

Net loss

$

(26,305

)

$

(24,113

)

$

(92,907

)

$

(82,339

)

 
Net loss per share, basic and diluted

$

(0.77

)

$

(0.98

)

$

(3.33

)

$

(3.36

)

 
Weighted average common shares outstanding, basic and diluted

 

34,342,664

 

 

24,545,360

 

 

27,890,846

 

 

24,473,092

 

KalVista Pharmaceuticals Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands, unaudited)
 

Years Ended

April 30,

 

2023

 

 

 

2022

 

 
Cash flows from operating activities
Net loss

$

(92,907

)

$

(82,339

)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

 

718

 

 

564

 

Stock-based compensation expense

 

9,922

 

 

11,086

 

Realized loss (gain) from sale of marketable securities

 

139

 

 

581

 

Non-cash operating lease expense

 

84

 

 

179

 

Amortization of premium on marketable securities

 

988

 

 

2,565

 

Foreign currency exchange loss (gain)

 

(1,618

)

 

1,552

 

Changes in operating assets and liabilities:
Research and development tax credit receivable

 

(2,316

)

 

(5,201

)

Prepaid expenses and other current assets

 

6,690

 

 

(9,280

)

Accounts payable

 

1,107

 

 

1,687

 

Accrued expenses

 

1,932

 

 

472

 

Net cash used in operating activities

 

(75,261

)

 

(78,134

)

 
Cash flows from investing activities
Purchases of marketable securities

 

(98,246

)

 

(136,920

)

Sales and maturities of marketable securities

 

140,857

 

 

195,711

 

Acquisition of property and equipment

 

(1,196

)

 

(931

)

Net cash provided by investing activities

 

41,415

 

 

57,860

 

 
Cash flows from financing activities
Issuance of common stock, net of offering expenses of $0.3 million

 

56,582

 

 

-

 

Issuance of pre-funded warrants, net of offering expenses

 

1,085

 

 

-

 

Issuance of common stock from equity incentive plans

 

449

 

 

1,581

 

Net cash provided by financing activities

 

58,116

 

 

1,581

 

Effect of exchange rate changes on cash and cash equivalents

 

1,236

 

 

(1,167

)

Net (decrease) increase in cash and cash equivalents

 

25,506

 

 

(19,860

)

Cash and cash equivalents at beginning of period

 

30,732

 

 

50,592

 

Cash and cash equivalents at end of period

$

56,238

 

$

30,732

 

 

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.